Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | GRK6 | P43250 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21716968 | 1.00 | PTGES (0.33) | PTGESPTGER4GSRHPGDKDM4E | |
| SCHEMBL21716930 | 0.94 | HPGD (0.33) | PTGESPTGER4GSRHPGDKDM4E | |
| SCHEMBL21716785 | 0.94 | HPGD (0.33) | PTGESPTGER4GSRHPGDKDM4E | |
| SCHEMBL21716261 | 0.94 | HPGD (0.33) | PTGESPTGER4GSRHPGDKDM4E | |
| SCHEMBL21716914 | 0.94 | HPGD (0.33) | PTGESPTGER4GSRHPGDKDM4E | |
| SCHEMBL21716692 | 0.93 | KDM4E (0.33) | PTGESPTGER4HPGDKDM4E | |
| SCHEMBL21716235 | 0.93 | KDM4E (0.33) | PTGESPTGER4HPGDKDM4E | |
| SCHEMBL23471696 | 0.92 | PTGES (0.34) | PTGESPTGER4KDM4E | |
| SCHEMBL21716977 | 0.92 | PTGES (0.34) | PTGESPTGER4KDM4E | |
| SCHEMBL23471680 | 0.92 | MAPK10 (0.33) | PTGESGSRHPGDKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2021-12-07 | — | — | US | disclosed |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | CYP1A1, CYP1B1, CRY1 | PTGES 1203/4885PTGER4 1167/4885GSR 3951/4885 |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CYP1A1, CYP1B1, CRY1 | PTGES 1203/4885PTGER4 1167/4885GSR 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.